Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just sold another 25% at .7628
I think you will have a great shot at it. I have to take my wife to the doctor for post surgery check up so I will be gone from computer, 5-6% after comm. for mornings work will be great with me
Just sold 25% of mine for .73
7+ million shares traded by 9:22 am, should prove interesting, just bought more at .67....... (not much all things relative)
noticed ddss up .11 in pre-market....
Bought some this morning for fun and hopefully profit .67,.68.70..... just saw one go past at .70 for 250,000 shares, so lots of interest in the snus sandbox this morning....
Thanks surf, I had already gone in and found the 1+/share in cash, no debt, and have purchased 4 times this morning for .67-.68.
Love to get in oversolds, hope this is one of them, love the cash on hand.
Do you know if Bayer has to give a payment for leaving the agreement?
What do you think today's upside might be? I have no idea what else they have in the pipeline, if anything....
Hello Surf, Do you see this one retesting the 1.43 mid August low?
I am showing it down .16 in premarket with last trade 2.85. 2.50 bid/ 2.80 ask. Thoughts?
Hello neuro, In case I have never mentioned it, please add me to the list of those that appreciate your informed, and what I deem, your upmost effort, that you continually put into your posts on this board.
Really, if only those that are so unhappy with current management would just SELL all their shares in the morning, and then maybe SHORT the stock with all the resources at their command, driving the stock down below a buck, and let the rest of us attempt to feast off their losses, well that would just be fine with me, and I am guessing many others on this board.
If the IND should fail, the stock falls not too far below a buck anyway, (imho,) so I only see upside to all the unhappy posters to SELL ASAP and let us feast.
I haven't lost money in 17 or so years in cor, corx, and I think I am in the best position ever, of course you have to be willing to sell once in a while, but what do I know?
Thanks again neuro.
Hello busker, What is your take on this news in relation to the share price? I have not been following Progen and would be grateful for any input you might provide.
Thanks for the updates.
Agreed, Geesh, the guy can't win here. If so many of our posters are THAT unhappy with his stewardship, than by all means SELL your shares on Monday. SELL them all, so those of us that think he is doing a good job, can buy those shares at an even further discount!
Hello JD, One of the great things about Cortex is that with each stepping stone of success, they become that much more attractive to being partnered with or bought outright.
Somewhere around 1990/1992 I purchased the old CORX more than once at 56 to 59 cents a share and even though they always had irons in the fire, they were a long way away from drugs on the shelf, so I sold for a good profit each time. I buy stocks to make money and I am always happy to take a profit. If I leave some on the table for the next person, so be it.
I am guessing that by your user name you traditionally invest in dividend paying investments like Alltel, BMY, bond funds, ect. You are a long way from those, but you are learning fast. Cash, debt, and burn rate are priority #1 in this sandbox. (imho)
I believe that we are closer now than ever to either striking a partnership deal, or having someone go after them lock, stock and barrel. The only way to really participate in that is to hold a relatively large position and wait for the hand to be played out.
All that being said, should the price rise significantly from here I would not hesitate to begin selling off chunks.
I have been using them with some really great success these past few weeks. Surf's energy level to me is astounding......
It seems pretty encouraging that CRGN rebounded during the afternoon on decent volume Friday. Seems that there are people out there accumulating the stock.
After my sells this morning, my remaining shares are costing me around 1.06/share. I am thinking of hanging on to them for a while to see what kind of positive pr's the new management comes out with.
I kind of like the way the shares are hanging in there so far this morning.....
Thanks again,
The fact that it didn't plunge on profit taking at the open, sure makes it look stronger than a lot I have seen, after such a good a pop as this one had yesterday.
Sold another 25% this morning, once I put that 17% in writing, it looked pretty good, so I went with it....
Thanks again.
Sold 25% this morning, might regret it, but booked 17% in a day on those shares.
Thanks again.....
You must get your energy from all that outdoor activity!
I agree, Seems like this year I have been buying over a period of week(s), but I thought I might be a little late from getting this off the bottom. Still will be watching/adding going forward.
Thanks again Surf for getting this board going.
Well I took the plunge this morning.
Began picking up shares this morning before price evened out.
I love the "end of june" 141 million cash on hand against 58 million shares out, trading at 1.28.
But truth be known I like that they named new management to at least appear that they are trying to turn things around.
Hoping for some positive pr.
8k and will be looking for more.
From my perspective, maybe the surf, aiming4, connection will be as good as HEPH
Encysive Says Court Dismisses Lawsuit____AP
Wednesday September 19, 7:24 am ET
Encysive Pharmaceuticals Says U.S. District Court Dismisses Class Action Litigation
HOUSTON (AP) -- Encysive Pharmaceuticals Inc. said Wednesday the U.S. District Court for the Southern District of Texas has dismissed, with prejudice, securities class action litigation against the company, four of its former officers and a current officer.
The suit was originally filed in September 2006 on behalf of shareholders who purchased stock in the company between Feb. 19, 2004 and March 24, 2006, and alleged the defendants violated federal securities laws by misrepresenting the company's business and prospects, thereby artificially inflating the price of shares.
"We are very pleased with the District Court's decision and believe that the ruling supports our position that the lawsuit was without merit," said George Cole, president and chief executive.
The company noted that the plaintiffs have a right to file an appeal to the U.S. Court of Appeals for the Fifth Circuit.
http://biz.yahoo.com/ap/070919/encysive_lawsuit.html?.v=1
Still didn't move the needle much. EOM
I picked up 5k to see if it bounces this am.
Are you picking up more in the premarket?
My little purchases are moving the needle.
I would think that the volume would start to die off, and then pps should follow. I will be looking to buy again as most lose interest.
Thanks again, hope the surfing is fine.....
Sold out my remaining HEPH this morning at 2.20, 2.25, and 2.19.
Very happy with this one. It's a long way from animal studies to viable product. Will watch for sure.
Thanks again.
Thanks for this one Surf1944,
Just got back from Vegas and BOOM.
Sold 25% of mine this morning, effectively lowering my remaining share price to 1.20.
Might wait and see if it bounces from all the scans tonight.
COR used to always peak second or third day, so we will see.
Thanks again
The Volume is showing on my screen at nearly DOUBLE the yahoo reported 3 month average. That should get it noticed for those who are not completely taking the holiday off.
I guess I'll be needing to take my laptop with me next week to Vegas. This one perking up and the COR Conference coming....
I was hoping to to leave it behind...
Thanks for helping me find this one, it just looked SO oversold to me.
I go out to cut the 4 acres and Wham. 80% of mine in this sector are up today. I had a final order in for just 600 shares to round out my holdings to an even thousand, didn't execute, but now I think I will just sit back and enjoy the ride.
To alertmeipp, and OT to JimHaynes,
alertmeipp, I bought more cor this past week from 1.83 down to 1.75, maybe 4000 shares total.
OT: Jimhaynes In one of your recent posts you mentioned that you had done well with Onyx. I was wondering if you knew much about Scott M. Freeman from Onyx.
Below is from the Aug. 8th Wall St Journal Online.
HOLLIS-EDEN PHARMACEUTICALS Inc. (San Diego) -- Scott M. Freeman was named chief medical officer, a new position with this drug company. Dr. Freeman, 50, was vice president, clinical development and operations with Onyx Pharmaceuticals Inc.
I have been investing in HEPH all week as I believe they are in a rather heavy oversold position.
Yahoo reports that as of June 7, 2007, HEPH had no debt, 52 million in cash and approx 29 million shares out. That works out to approx 1.80 an outstanding share in CASH. The stock is trading at around 1.50 now.
Anyway, I was curious if you know much about Mr. Freeman from your reported good experience with Onyx.
Thanks for any insight you may be able to provide.
700 of those last minute ones came this way, was trying for a final 1000 but last 300 didn't make it.
Still adding today, about 3% of the trading volume, (not very much,) love the cash on hand and what I interpret as a large oversold move. Time will tell but all I bought was this HEPH and COR this week.
Best of luck.
Sorry, Source for press realease:
http://biz.yahoo.com/bw/070830/20070830005441.html?.v=1
Press Release Source: Cortex Pharmaceuticals, Inc.
Cortex's CEO Roger Stoll to Speak at the Roth Capital Partners New York Conference on September 5, 2007
Thursday August 30, 9:00 am ET
IRVINE, Calif.--(BUSINESS WIRE)--Cortex Pharmaceuticals, Inc. (AMEX: COR - News) Chairman, President and CEO, Roger G. Stoll, Ph.D., will speak at the Roth Capital Partners New York Conference at the Westin New York at Times Square on Wednesday, September 5, 2007 at 4:00 pm EDT (1:00 pm PDT) in the Broadway III conference room. The conference will feature over 230 small-cap companies across a broad spectrum of sectors, including technology, healthcare, financial services and consumer products.
ADVERTISEMENT
Dr. Stoll will give a brief corporate overview, as well as provide an update on the latest clinical developments, including the recent FDA response that gave Cortex the go-ahead to immediately resume enrollment in their CX717 Alzheimer's positron emission tomography (PET) scan study at all requested dose levels. The study was originally designed with doses of 200mg, 600mg, and 1200mg to be administered to the patients. However, the FDA had previously limited the dose levels such that the 600mg and 1200mg doses could not be administered. The new protocol approved by the FDA allows a return to the original dose levels, with the upper dose being 1200mg. With the removal of the foregoing dose restrictions, the Company can now resume study of CX717 at all dose levels defined in its original protocol.
Dr. Stoll will also discuss recent new developments obtained from the University of Alberta in animal studies which demonstrate that both High and Low impact AMPAKINE® drugs are effective in overcoming the respiratory depression caused by opiate analgesic compounds. The potential for both acute and chronic applications of AMPAKINE drugs for the treatment of respiratory depression disorders may be realized due to these findings. The Company is currently assessing both CX717 and CX701 for rapidly moving forward with clinical trials for acute applications in respiratory depression.
Dr. Stoll will also provide an update on other clinical developments and strategies. Cortex plans to file an Investigational New Drug ("IND") application with the Psychiatric Drug Products Division of the FDA for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults in early September 2007. Also, as a result of the completion of the recently announced financing of Cortex, the Company anticipates developing both CX701 and CX1763 as clinical drug candidates. Cortex expects to file an IND for CX701 during the fourth quarter of 2007 and CX1763 is undergoing IND-enabling studies as well. Therefore, the Company is planning to have three AMPAKINE compounds in clinical development by mid-2008. Dr. Roger Stoll, the Chief Executive Officer and Chairman of Cortex stated that "having multiple compounds in our drug development pipeline has been a major objective for Cortex and with the recent financing we have the financial means to work toward a realization of those objectives for our Company during 2008. A more robust development pipeline will improve the chances for achieving clinical success."
A live webcast of the presentation can be accessed by logging onto http://www.wsw.com/webcast/roth13/cor/ and a replay will be available for 45 days following the conference.
Cortex Pharmaceuticals, Inc.
Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for neurological and psychiatric disorders. Cortex is pioneering a class of proprietary pharmaceuticals called AMPAKINE compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in Alzheimer's disease. Many psychiatric diseases, including schizophrenia, occur as a result of imbalances in the brain's neurotransmitter system. These imbalances may be improved by using the AMPAKINE technology. Cortex has an alliance with N.V. Organon for the treatment of schizophrenia and depression. In December 2006 Cortex terminated the research collaboration with Servier enabling Cortex to pursue the use of AMPAKINE compounds in the treatment of neurodegenerative diseases on a global basis. Servier retained the right to select up to three compounds developed during the collaboration for further development for the treatment of neurodegenerative diseases. Cortex may receive additional milestones and royalties if either Organon or Servier is successful in developing and commercializing AMPAKINE compounds. For additional information regarding Cortex, please visit Cortex Pharmaceuticals' Website at www.cortexpharm.com.
Forward-Looking Statement
Note - This press release contains forward-looking statements concerning the Company's research and development activities. The success of such activities depends on a number of factors, including the risks that the Company's proposed compounds may at any time be found to be unsafe or ineffective for the indications under clinical test and that clinical studies may at any point be suspended or take substantially longer than anticipated to complete. The forward-looking statements are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Cortex, all as more fully described in the risk factors and other matters set forth in Cortex's Annual Report on Form 10-K for the year ended December 31, 2006, and Cortex's other filings with the Securities and Exchange Commission, As discussed in the Company's Securities and Exchange Commission filings, the Company's proposed products will require additional research, lengthy and costly clinical testing and regulatory approval. AMPAKINE compounds are investigational drugs and have not been approved for the treatment of any disease. Cortex disclaims any intent or obligation to update any forward-looking statements.
Contact:
Cortex Pharmaceuticals, Inc.
Roger G. Stoll, Ph.D.
Chairman, President and CEO
949-727-3157
or
The Investor Relations Group
Investor:
Erika Moran/Dian Griesel, Ph.D.
Media:
Janet Vasquez/Lynn Granito
212-825-3210
--------------------------------------------------------------------------------
Source: Cortex Pharmaceuticals, Inc.
Still adding today, last trade didn't execute. I usually build a position over one to several weeks, in effect dollar cost averaging within a short window. Occasionally I miss a move up, but I also avoid some scalps like COR last friday. Always on the lookout for oversolds!
This stocks does seem to have firmed up pretty well. That drop to 1.45 today seemed like it only lasted only seconds. One of my trades executed during that drop.
Thanks for the updates.
It took 11 fills and almost an hour today to get my first 1000 shares at 1.50, including trades of 3,8,8,9,12, and 20 shares. I had never seen anything quite like it. The small trades didn't show up on my level 2 as I only see round lots there, and most of the executions showed as sells at 1.50, rather than buys, but my orderbook would immediately show them as buys in my account. I was able to get another 550 of 1000 right at 3:59 as the price dipped just before the close.
Thanks for the price targets.
Someone has sold some to me over the last couple days. I am taking the silence as a positive and have tipped my toes in a little deeper. Not that easy to do with all the negatives on this board, many deserved, but the way I see it, management now has cash, and hopefully good news/press releases will start flowing.